查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1873335

全球移植用HLA型检测市场

HLA Typing for Transplant
出版日期: | 出版商: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计到2030年，全球用于移植的HLA型检测市场规模将达到15亿美元。

2024年全球用于移植的HLA型检测市场规模预计为11亿美元，预计到2030年将达到15亿美元，在分析期间（2024-2030年）内复合年增长率（CAGR）为5.3%。本报告分析的非分子检测技术细分市场预计将以4.4%的复合年增长率成长，并在分析期间结束时达到8.691亿美元。分子检测技术细分市场预计在分析期间将以6.7%的复合年增长率成长。

美国市场规模估计为2.96亿美元，而中国市场预计将以5.1%的复合年增长率成长。

预计到2024年，美国移植HLA型检测市场规模将达2.96亿美元。作为世界第二大经济体，中国预计到2030年市场规模将达到2.329亿美元，在2024年至2030年的分析期内，年复合成长率（CAGR）为5.1%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的年复合成长率分别为5.1%和4.3%。在欧洲，德国的年复合成长率预计约为4.6%。

全球移植HLA型检测市场－主要趋势与驱动因素摘要

HLA型检测是器官移植成功的关键吗？

人类白血球抗原（ HLA型检测是器官移植的基石技术，但为什么这个基因配对过程对移植成功如此关键？ HLA型检测可以识别白血球表面的特定抗原，这些抗原在免疫系统区分自身和非自身方面发挥关键作用。这些抗原对于器官和组织的相容性至关重要，不匹配会导致移植器官排斥。在移植手术中， HLA型检测确保捐赠者和受体之间尽可能高的免疫相容性，从而降低器官排斥的风险并提高移植器官的存活率。

HLA型检测的优点在于能够精准匹配供体和受体的免疫特征，从而降低急性或慢性排斥等併发症。这不仅对固态器官移植（肾臟、肝臟、心臟和肺臟）至关重要，对造血干细胞移植（骨髓）也同样重要，因为在造血干细胞移植中，精准的HLA配型对于预防移植物抗宿主疾病（GVHD）至关重要。透过了解患者的HLA特征并找到最佳捐赠者，移植专家可以提高移植成功率，并帮助患者避免可能损害移植器官的免疫反应。随着器官移植需求的成长和技术的进步， HLA型检测仍然是这个拯救生命的医学领域中最佳疗效的关键工具。

移植领域HLA型检测技术有哪些进展？

技术进步显着提高了HLA型检测的准确性、速度和可及性，使移植供体-受体匹配过程更加高效精准。其中一个最重要的进展是分子技术的引入，特别是基于聚合酵素链锁反应（PCR）的方法和次世代定序（NGS）。传统上，血清学检测用于鑑定HLA抗原，但其检测细微突变和实现高分辨率分型的能力有限。 PCR和NGS技术的出现极大地提高了HLA型检测的分辨率和准确性，能够识别仅相差几个碱基对的特定等位基因，这对于精细调整供体-受体相容性至关重要。

次世代定序（ NGS）透过提供高通量、全面的HLA基因讯息，彻底革新了HLA型检测。 NGS能够并行定序多个HLA基因，使移植团队能够更详细地了解供体和受体的HLA等位基因。这种高解析度分型在造血干细胞移植中尤其重要，因为即使是基因层面的微小错配也可能导致移植物抗宿主疾病等严重併发症。 NGS的另一个优点在于能够识别传统方法难以检测到的罕见和新型等位基因，从而进一步提高捐赠者选择的准确性，并降低排斥反应和免疫併发症的风险。

HLA型检测的另一项重大进展是应用了新一代交叉配型检测技术，有助于评估抗体介导排斥反应的可能性。这些检测采用先进的流式细胞技术和Luminex技术来检测受者血液中的供体特异性抗体（DSA）。 DSA是抗体介导排斥反应的主要风险因素，高解析度HLA型检测结合详细的交叉配对，使移植团队能够更准确地评估排斥风险，并根据患者的需求制定个人化的免疫抑制治疗方案。这些交叉配型技术使得移植计画的发展更加灵活，从而降低了移植失败的风险，并改善了长期预后。

高解析度HLA型检测也受惠于软体工具和生物资讯学平台的进步，这些进步使得序列资料的解读更加快速且准确。先进的演算法能够即时分析大量的序列数据，使移植中心能够快速匹配供体和受体。这些平台不仅加快了流程，还降低了人为错误的机率，提高了HLA匹配的可靠性。此外，生物资讯学工具还能辨识HLA抗原决定位错配——HLA分子中可能引发免疫反应的微小差异——从而实现供体和受体之间更精确的匹配。

人工智慧 (AI) 和机器学习的兴起是改变HLA型检测的另一个领域。人工智慧驱动的系统正在开发中，透过分析大量的 HLA 谱和移植结果资料集，更有效地预测供体-受体相容性。这些系统模拟不同 HLA 匹配之间潜在的免疫反应，有助于优化捐赠者选择并降低排斥风险。透过利用预测分析，人工智慧最终可能使移植中心能够进一步改进其 HLA 匹配演算法，即使在无法实现完美 HLA 匹配的情况下，也有可能提高移植成功率。

快速HLA型检测技术的进步也使得紧急移植病例能够及时进行配型。在患者病情迅速恶化的情况下，传统的HLA型检测方法耗时过长，可能无法确保移植成功。然而，基于PCR的快速技术现在可以在数小时内而非数天内提供HLA型检测结果，从而在紧急情况下实现更快的配型。这对于肝臟、心臟和肺移植尤其重要，因为时间至关重要，患者需要紧急手术。

最后，用于活体捐赠者移植的HLA型检测技术的进步正在提高肾臟移植等手术的安全性和成功率。透过提高活体供体和受体之间的相容性， HLA型检测降低了慢性排斥的风险，从而改善了供体和受体的长期预后。此外，快速且准确的HLA型检测也提高了肾臟交换计画的效率，在肾臟交换计画中，活体捐赠者交换肾臟以寻找更佳的HLA匹配，使更多患者能够找到合适的捐赠者，同时降低排斥风险。

为什么HLA型检测对器官移植的成功至关重要？

HLA型检测对于器官移植的成功至关重要，因为它在决定捐赠器官和组织能否被受体免疫系统接受方面起着核心作用。细胞表面的HLA分子将外来物质呈现给免疫系统，一旦侦测到不匹配，就会引发免疫反应。在器官移植中，如果供体的HLA抗原与受体的HLA抗原有显着差异，受体的免疫系统可能会将器官识别为外来物并发动攻击，导致急性或慢性排斥反应。因此，准确的HLA型检测有助于更精确地匹配供体和受体，最大限度地降低排斥反应的风险，并确保移植器官的长期存活。

在肾臟移植中， HLA型检测已被证实对移植结果有显着影响。接受HLA高度匹配器官的患者，其排斥率往往较低，移植器官存活时间较长，而接受HLA匹配度较低的器官的患者则不然。这一点对于「高度致敏」的患者尤其重要，因为他们可能由于先前移植、怀孕或输血而获得了针对HLA抗原的抗体。虽然为这些患者寻找匹配的供体更具挑战性，但精准的HLA型检测结合脱敏通讯协定，可以帮助确保获得匹配的器官，并降低抗体介导的排斥反应风险。

在造血干细胞移植（HSCT）中，HLA相容性尤其重要。供体和受体HLA等位基因不匹配会导致移植物抗宿主疾病（GVHD），这是一种可能危及生命的疾病，移植的免疫细胞会攻击受体本身的组织。由于即使是HLA等位基因的轻微不匹配也可能导致严重的GVHD，因此找到完全或近乎完全匹配的HLA匹配对于降低这种併发症的风险至关重要。高解析度HLA型检测在HSCT中至关重要，因为它能够精确匹配主要HLA位点（例如HLA-A、HLA-B、HLA-C和HLA-DRB1）和次要位点。因此， HLA型检测有助于预防移植干细胞的排斥反应以及GVHD等严重併发症。

HLA型检测对于肝臟、心臟和肺移植的成功至关重要。然而，这些移植对HLA匹配的要求可能不如肾臟移植或造血干细胞移植（HSCT）严格。在这些情况下，其他因素，例如ABO血型相容性和器官大小相容性，也同样重要。但是，研究表明，更好的HLA匹配仍然可以透过降低排斥风险和提高长期移植存活率来改善预后。良好的HLA匹配可以显着影响长期存活率，尤其是在心臟和肺移植中，因为这些移植的捐赠器官稀缺，且存活率低于肾臟移植。

在活体器官移植（例如肾臟移植）中， HLA型检测能够帮助移植团队优化捐赠者之间的匹配度，从而提高移植成功率。在活体肾臟捐赠中， HLA型检测用于确定捐赠者的匹配度。当无法找到完全匹配的捐赠者时， HLA型检测也可以用于促进肾臟交换配对。这使得活体器官移植方案更加灵活，增加了潜在的匹配数量，使患者能够更快地接受移植。通常情况下，活体器官的HLA匹配度会优于已故捐赠者器官。

除了器官和干细胞移植之外， HLA型检测在输血医学中也发挥着至关重要的作用，因为HLA不匹配会导致输血相关反应，例如输血相关性急性肺损伤（TRALI）。在血小板输注中， HLA型检测透过HLA抗体配对患者和供者，确保输血的安全性和有效性。由国家骨髓捐赠者计划等机构运营的骨髓库利用HLA型检测来识别需要干细胞移植的患者的潜在供者，从而显着提高找到匹配供者的几率。

HLA型检测不仅对移植手术的即时成功至关重要，而且对受者的长期健康至关重要。 HLA配对不佳会导致慢性排斥反应，这是一个缓慢进行性的过程，最终会导致移植器官衰竭。慢性排斥反应是长期移植失败的主要原因之一，尤其是在肾臟和心臟移植。透过提高捐赠者和受者之间的HLA配对，移植中心可以降低慢性排斥反应的发生率，并确保移植器官在受者有生之年，或至少在未来许多年内持续发挥作用。

哪些因素正在推动移植HLA型检测市场的成长？

移植HLA型检测市场的成长受多种关键因素驱动，包括器官和干细胞移植需求的不断增长、 HLA型检测技术的进步、慢性病盛行率的上升以及全球移植登记库的扩容。其中一个关键驱动因素是器官移植需求的不断增长，这主要是由于末期肾功能衰竭（ESRD）、肝功能衰竭、心臟衰竭和血液癌症等疾病的发生率不断上升所致。随着移植等待名单上的患者人数持续增加，对准确高效的HLA型检测以匹配供体和受体的需求也相应增长。

HLA型检测技术的进步，特别是次世代定序（NGS）技术的引入，也推动了市场成长。 NGS技术使高解析度HLA型检测更加精准、快速且经济高效，成为移植中心降低排斥风险、优化治疗效果的首选方法。高精度定序整个HLA区域的能力提高了供体选择标准，并提升了移植成功率，尤其是在高度致敏患者和涉及罕见HLA等位基因的复杂病例中。随着越来越多的移植中心采用NGS进行HLA型检测，预计对这些高解析度技术的需求将会增加，从而推动市场扩张。

糖尿病、高血压和癌症等慢性疾病的日益普及也是推动HLA型检测市场成长的因素之一。这些疾病是导致器官衰竭的主要原因，尤其是肾臟、肝臟和心臟衰竭。随着这些疾病在全球的负担持续加重，需要器官移植的患者人数也不断增加。 HLAHLA型检测对于确保这些患者获得相容的器官或干细胞至关重要，它能够改善移植效果，并减少因排斥或移植失败而需要再次移植的情况。

骨髓和器官捐赠者登记库的扩充也是HLA型检测市场成长的主要驱动力。诸如美国的「Be The Match」组织和国际登记库等机构正致力于增加HLA型检测捐赠者的数量，尤其是在造血干细胞移植领域。随着越来越多的人登记成为潜在捐赠者，对快速、准确的HLA型检测以寻找匹配捐赠者的需求也随之增加。特别是，干细胞移植志愿捐赠者的增加，使得对高分辨率HLA型检测的需求显着增长，因为精准配型对于降低移植物抗宿主疾病等併发症的风险至关重要。

对精准医疗和个人化医疗日益增长的关注也是推动市场成长的因素之一。 HLAHLA型检测是移植领域个人化治疗的核心，它能将每位患者独特的基因组成与最合适的捐赠者配对，从而确保最佳的治疗效果。基因组学的进步以及分子诊断在移植医学中的应用，使得人们更加关注个人化治疗方案，包括基于HLA不相容程度的个人化免疫抑制疗法。这种向精准医疗的转变预计将进一步扩大HLA型检测服务的需求。

政府推行的促进器官捐赠和移植的措施以及相关的医疗政策，也推​​动了HLA型检测市场的成长。许多国家都在投资公共卫生宣传活动，旨在意识提升，并改善移植基础设施。此外，器官移植的法规结构和报销政策也日趋完善，使患者更容易获得挽救生命的移植手术。随着需要移植的患者人数不断增加，政府和医疗系统加强支持力度，预计将进一步刺激HLA型检测的需求。

最后，交叉配对试验的进步，例如利用Luminex和流式细胞技术检测供体特异性抗体（DSA），正在推动对全面的HLA型检测和交叉配对通讯协定的需求。这些技术使移植团队能够更准确地评估抗体介导的排斥反应风险，从而实现供体和受体更精准的配型，进而改善移植结果。交叉配对试验与高解析度HLA型检测的日益普及，提高了移植器官的长期存活率，进一步推动了市场成长。

随着器官和干细胞移植需求的不断增长、 HLA型检测技术的进步以及全球精准医疗的兴起， HLA型检测市场预计将显着增长。在医疗系统持续将移植成功率和患者预后放在首位的情况下， HLA型检测仍将是确保捐赠者相容性、降低排异风险以及提高移植受者长期存活率的关键工具。

部分：

技术（非分子检测、分子检测）、产品和服务（试剂和耗材、设备、软体和服务）、应用（诊断、研究）

受访公司范例

  • Abbott Laboratories
  • Affymetrix, Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Immucor, Inc.
  • Luminex Corporation
  • Qiagen NV
  • Thermo Fisher Scientific, Inc.

人工智慧集成

我们正在利用检验的专家内容和人工智慧工具，革新市场和竞争情报分析。

Global Industry Analysts 并没有依赖通用的 LLM 或查询产业专用的SLM，而是建立了一个由世界各地领域专家精心整理的内容库，包括视讯转录、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

我们最新发布的报告纳入了关税对区域市场的影响，正如全球产业分析师预测的那样，关税将改变企业的竞争地位，而企业的竞争地位将取决于其总部所在地、製造地以及进出口（成品和OEM产品）。这种复杂多变的市场现实将透过微观和宏观市场动态影响竞争对手，包括销货成本增加、盈利下降以及供应链重组。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章 市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲
  • 亚太地区
  • 世界其他地区

第四章 竞赛

简介目录
Product Code: MCP12411

Global HLA Typing for Transplant Market to Reach US$1.5 Billion by 2030

The global market for HLA Typing for Transplant estimated at US$1.1 Billion in the year 2024, is expected to reach US$1.5 Billion by 2030, growing at a CAGR of 5.3% over the analysis period 2024-2030. Non-Molecular Assay Technology, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$869.1 Million by the end of the analysis period. Growth in the Molecular Assay Technology segment is estimated at 6.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$296.0 Million While China is Forecast to Grow at 5.1% CAGR

The HLA Typing for Transplant market in the U.S. is estimated at US$296.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$232.9 Million by the year 2030 trailing a CAGR of 5.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.1% and 4.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Global HLA Typing for Transplant Market - Key Trends and Drivers Summarized

Is HLA Typing the Key to Success in Organ Transplantation?

HLA typing, or human leukocyte antigen typing, is a cornerstone of organ transplantation, but why is this genetic matching process so vital for transplant success? HLA typing involves identifying specific antigens on the surface of white blood cells that play a critical role in the immune system’s ability to recognize self from non-self. These antigens are crucial in organ and tissue compatibility, as mismatches can lead to rejection of the transplanted organ. In transplantation, HLA typing ensures that the donor and recipient are as immunologically compatible as possible, reducing the risk of organ rejection and improving graft survival.

The appeal of HLA typing lies in its ability to match the donor’s and recipient’s immune profiles closely, reducing complications such as acute or chronic rejection. It is essential not only for solid organ transplants (kidneys, liver, heart, lungs) but also for hematopoietic stem cell transplants (bone marrow), where precise HLA matching is critical to prevent graft-versus-host disease (GVHD). By understanding the patient’s HLA profile and finding the best donor match, transplant specialists can improve the success rates of transplants and help patients avoid the immune responses that might otherwise compromise the graft. As the demand for organ transplants grows and technology advances, HLA typing remains a critical tool for achieving the best possible outcomes in this life-saving medical field.

How Has Technology Advanced HLA Typing for Transplantation?

Technological advancements have significantly improved the accuracy, speed, and accessibility of HLA typing, transforming it into a more efficient and precise process for matching donors and recipients in transplantation. One of the most important developments has been the introduction of molecular techniques, particularly polymerase chain reaction (PCR)-based methods and next-generation sequencing (NGS). In the past, serological testing was used to identify HLA antigens, but these methods had limitations in detecting subtle variations and providing high-resolution typing. The shift to PCR and NGS has dramatically improved the resolution and accuracy of HLA typing, allowing for the identification of specific alleles that differ by only a few nucleotides, which can be critical in fine-tuning donor-recipient compatibility.

Next-generation sequencing has revolutionized HLA typing by providing high-throughput, comprehensive genetic information about HLA loci. NGS allows for the sequencing of multiple HLA genes in parallel, giving transplant teams a more detailed understanding of both donor and recipient HLA alleles. This high-resolution typing is particularly important in hematopoietic stem cell transplants, where even small mismatches at the genetic level can lead to serious complications like graft-versus-host disease. NGS also has the advantage of identifying rare or novel alleles that might not be detectable with older methods, further enhancing the precision of donor selection and reducing the risk of rejection or immune complications.

Another major advancement in HLA typing is the use of next-generation crossmatch assays, which help assess the potential for antibody-mediated rejection. These assays use advanced flow cytometry and Luminex technology to detect donor-specific antibodies (DSAs) in the recipient’s blood. DSAs are a major risk factor for antibody-mediated rejection, and by combining high-resolution HLA typing with detailed crossmatch testing, transplant teams can more accurately assess the risk of rejection and tailor immunosuppressive therapies to the patient’s needs. These crossmatch technologies allow for a more dynamic approach to transplant planning, reducing the likelihood of graft loss and improving long-term outcomes.

High-resolution HLA typing has also benefited from advances in software tools and bioinformatics platforms, which enable faster, more accurate interpretation of sequencing data. Sophisticated algorithms can now analyze large volumes of sequencing data in real time, ensuring that transplant centers can quickly match donors and recipients. These platforms not only speed up the process but also reduce the likelihood of human error, improving the reliability of HLA matching. Additionally, bioinformatics tools can identify HLA epitope mismatches-small differences in HLA molecules that might trigger an immune response-allowing for even more refined matching between donors and recipients.

The rise of artificial intelligence (AI) and machine learning is another area transforming HLA typing. AI-driven systems are being developed to predict donor-recipient compatibility more effectively by analyzing large datasets of HLA profiles and transplant outcomes. These systems can model the potential immune responses between different HLA matches, helping to optimize donor selection and reduce the risk of rejection. By leveraging predictive analytics, AI could eventually allow transplant centers to refine HLA matching algorithms further, improving transplant success rates even in cases where perfect HLA matches are not available.

Advances in rapid HLA typing methods have also made it possible to provide timely matches for urgent transplant cases. In cases where a patient’s condition deteriorates quickly, traditional methods of HLA typing may take too long to ensure a successful transplant. However, rapid PCR-based techniques can now provide HLA typing results in a matter of hours rather than days, allowing for faster matching in emergency situations. This is particularly important in liver, heart, or lung transplants, where time is of the essence and patients are often in critical need of immediate surgery.

Finally, advancements in HLA typing for living donor transplants have improved the safety and success of procedures such as kidney transplants. By ensuring a closer match between living donors and recipients, HLA typing has reduced the risk of chronic rejection, leading to better long-term outcomes for both donor and recipient. Additionally, paired kidney exchanges, where living donors swap kidneys to find better HLA matches, have been made more effective through rapid and precise HLA typing, helping more patients find suitable donors while maintaining low rejection risks.

Why Is HLA Typing Critical for Successful Organ Transplants?

HLA typing is critical for successful organ transplants because it plays a central role in determining whether a donor’s organ or tissue will be accepted by the recipient’s immune system. The HLA molecules on the surface of cells are responsible for presenting foreign substances to the immune system, triggering an immune response if a mismatch is detected. In organ transplantation, if the donor’s HLA antigens are too different from the recipient’s, the recipient’s immune system may recognize the organ as foreign and mount an attack, leading to acute or chronic rejection. Therefore, accurate HLA typing helps match donors and recipients more precisely, minimizing the risk of rejection and ensuring long-term graft survival.

In kidney transplantation, HLA typing has been shown to significantly influence graft outcomes. Patients with a high degree of HLA matching tend to experience fewer rejection episodes, and their grafts tend to last longer compared to patients with poorly matched organs. This is especially important in highly sensitized patients-those who have developed antibodies against HLA antigens due to prior transplants, pregnancies, or blood transfusions. For these patients, finding a well-matched donor is more challenging, but precise HLA typing, combined with desensitization protocols, can help them receive compatible organs and reduce the risk of antibody-mediated rejection.

In hematopoietic stem cell transplants (HSCT), HLA matching is even more critical. Mismatches between donor and recipient HLA alleles can lead to graft-versus-host disease (GVHD), a potentially life-threatening condition where the transplanted immune cells attack the recipient’s tissues. Even minor mismatches in HLA alleles can result in severe GVHD, so finding a perfect or near-perfect HLA match is essential for reducing the risk of this complication. High-resolution HLA typing is crucial in HSCT to ensure that both the major HLA loci (such as HLA-A, HLA-B, HLA-C, and HLA-DRB1) and minor loci are carefully matched. As a result, HLA typing helps prevent both rejection of the transplanted stem cells and serious complications like GVHD.

HLA typing is also essential for the success of liver, heart, and lung transplants, although the level of HLA matching required for these transplants may not be as strict as for kidney or HSCT. In these cases, other factors like ABO blood type matching and organ size compatibility are also important. However, research has shown that better HLA matching can still improve outcomes by reducing the risk of rejection and improving graft longevity. In particular, for heart and lung transplants, where donor organs are scarce and survival rates are lower than in kidney transplants, achieving a good HLA match can significantly impact long-term survival.

For living donor transplants, such as in kidney transplantation, HLA typing enables transplant teams to optimize the match between donors and recipients, improving the likelihood of success. In living kidney donation, HLA typing is used to determine the compatibility between donor and recipient, and in some cases, where a perfect match is not available, HLA typing is used to facilitate paired kidney exchanges. This allows for a more flexible approach to living donor transplants, increasing the number of possible matches and helping patients receive transplants sooner, often with better HLA matches than deceased donor organs.

Beyond organ and stem cell transplantation, HLA typing also plays a critical role in transfusion medicine, where HLA mismatches can cause transfusion-related reactions such as transfusion-related acute lung injury (TRALI). In platelet transfusions, HLA typing is used to match donors with patients who have developed HLA antibodies, ensuring that transfusions are safer and more effective. In bone marrow registries, such as those run by organizations like the National Marrow Donor Program, HLA typing is used to identify potential donors for patients in need of stem cell transplants, significantly improving the chances of finding compatible matches.

HLA typing is not only important for the immediate success of the transplant but also for the long-term health of the recipient. Poor HLA matching can lead to chronic rejection, a slow and progressive process that eventually causes the transplanted organ to fail. Chronic rejection is one of the leading causes of late graft loss, particularly in kidney and heart transplants. By improving the HLA match between donor and recipient, transplant centers can reduce the likelihood of chronic rejection, ensuring that the transplant remains functional for many years, if not for the lifetime of the recipient.

What Factors Are Driving the Growth of the HLA Typing for Transplant Market?

The growth of the HLA typing for transplant market is driven by several key factors, including the rising demand for organ and stem cell transplants, advancements in HLA typing technologies, the increasing prevalence of chronic diseases, and the expansion of transplant registries worldwide. One of the primary drivers is the growing need for organ transplants, fueled by the rising incidence of conditions such as end-stage renal disease (ESRD), liver failure, heart failure, and hematological cancers. As the number of patients waiting for transplants continues to rise, the demand for accurate and efficient HLA typing to match donors and recipients has grown correspondingly.

Advancements in HLA typing technologies, particularly the adoption of next-generation sequencing (NGS), have also contributed to market growth. NGS has made high-resolution HLA typing more accurate, faster, and cost-effective, making it the preferred method for transplant centers seeking to minimize rejection risks and optimize outcomes. The ability to sequence entire HLA regions with high precision has improved donor selection and increased the success rates of transplants, particularly in complex cases involving highly sensitized patients or rare HLA alleles. As more transplant centers adopt NGS for HLA typing, the demand for these high-resolution techniques is expected to increase, driving market expansion.

The increasing prevalence of chronic diseases, such as diabetes, hypertension, and cancer, is another factor contributing to the growth of the HLA typing market. These conditions are leading causes of organ failure, particularly for kidneys, livers, and hearts. As the global burden of these diseases continues to rise, so does the number of patients requiring transplants. HLA typing is essential for ensuring that these patients receive compatible organs or stem cells, improving transplant outcomes and reducing the need for re-transplantation due to rejection or graft failure.

The expansion of bone marrow and organ donor registries is also playing a significant role in driving the HLA typing market. Organizations such as Be The Match in the United States and international registries are working to increase the number of HLA-typed donors, particularly for hematopoietic stem cell transplants. As more individuals register as potential donors, the need for rapid and accurate HLA typing to identify matches grows. In particular, the rise of volunteer donors for stem cell transplants has created a significant demand for high-resolution HLA typing, as precise matching is critical for reducing the risk of complications like graft-versus-host disease.

The growing emphasis on precision medicine and personalized healthcare is another factor driving market growth. HLA typing is central to the personalized approach in transplantation, where each patient’s unique genetic makeup must be matched to the most suitable donor to ensure the best possible outcome. Advances in genomics and the integration of molecular diagnostics in transplant medicine have increased the focus on individualized treatment plans, which include tailored immunosuppressive regimens based on the degree of HLA mismatch. This shift toward precision medicine is expected to further expand the demand for HLA typing services.

Government initiatives and healthcare policies promoting organ donation and transplantation are also contributing to the growth of the HLA typing market. Many countries are investing in public health campaigns to raise awareness about organ donation and improve the infrastructure for transplantation. Additionally, regulatory frameworks and reimbursement policies for organ transplants are becoming more favorable, making it easier for patients to access life-saving transplant procedures. This increased support from governments and healthcare systems is expected to drive further growth in the demand for HLA typing as more patients are referred for transplantation.

Finally, advancements in crossmatch testing, including the use of Luminex and flow cytometry techniques to detect donor-specific antibodies (DSAs), are driving demand for comprehensive HLA typing and crossmatching protocols. These techniques allow transplant teams to assess the risk of antibody-mediated rejection more accurately, improving transplant outcomes by enabling more precise donor-recipient matching. The increasing use of crossmatch testing, combined with high-resolution HLA typing, is leading to better long-term graft survival rates, further supporting market growth.

With the increasing need for organ and stem cell transplants, technological advancements in HLA typing, and the global shift toward precision medicine, the HLA typing market is poised for significant growth. As healthcare systems continue to prioritize transplant success and patient outcomes, HLA typing will remain a critical tool for ensuring compatibility, reducing rejection risks, and improving the long-term survival of transplant recipients.

SCOPE OF STUDY:

The report analyzes the HLA Typing for Transplant market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (Non-Molecular Assay, Molecular Assay); Products & Services (Reagents & Consumables, Instruments, Software & Services); Application (Diagnostics, Research)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 41 Featured) -

  • Abbott Laboratories
  • Affymetrix, Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Immucor, Inc.
  • Luminex Corporation
  • Qiagen NV
  • Thermo Fisher Scientific, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • Global Economic Update
    • HLA Typing for Transplant - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Organ Transplantation Drives Growth in HLA Typing Market
    • Expansion of Bone Marrow and Stem Cell Transplant Programs Spurs Adoption of HLA Typing for Transplantation
    • Role of HLA Typing in Supporting Research on Immunotherapy and Autoimmune Diseases Expands Market Reach
    • Role of HLA Typing in Enhancing Success Rates in Kidney and Liver Transplants Fuels Market Growth
    • Growth in Use of HLA Typing in Allogeneic and Autologous Transplantation Strengthens Market
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Reagents & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Reagents & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Reagents & Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Software & Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Non-Molecular Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Non-Molecular Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 12: World 15-Year Perspective for Non-Molecular Assay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Molecular Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Molecular Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 15: World 15-Year Perspective for Molecular Assay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 18: World 15-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 21: World 15-Year Perspective for Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 22: World HLA Typing for Transplant Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for HLA Typing for Transplant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for HLA Typing for Transplant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for HLA Typing for Transplant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • HLA Typing for Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for HLA Typing for Transplant by Products & Services - Percentage Breakdown of Value Sales for Reagents & Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for HLA Typing for Transplant by Technology - Percentage Breakdown of Value Sales for Non-Molecular Assay and Molecular Assay for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for HLA Typing for Transplant by Application - Diagnostics and Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for HLA Typing for Transplant by Application - Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for HLA Typing for Transplant by Application - Percentage Breakdown of Value Sales for Diagnostics and Research for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for HLA Typing for Transplant by Products & Services - Percentage Breakdown of Value Sales for Reagents & Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for HLA Typing for Transplant by Technology - Percentage Breakdown of Value Sales for Non-Molecular Assay and Molecular Assay for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for HLA Typing for Transplant by Application - Diagnostics and Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for HLA Typing for Transplant by Application - Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for HLA Typing for Transplant by Application - Percentage Breakdown of Value Sales for Diagnostics and Research for the Years 2015, 2025 & 2030
  • JAPAN
    • HLA Typing for Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for HLA Typing for Transplant by Products & Services - Percentage Breakdown of Value Sales for Reagents & Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for HLA Typing for Transplant by Technology - Percentage Breakdown of Value Sales for Non-Molecular Assay and Molecular Assay for the Years 2015, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for HLA Typing for Transplant by Application - Diagnostics and Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for HLA Typing for Transplant by Application - Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for HLA Typing for Transplant by Application - Percentage Breakdown of Value Sales for Diagnostics and Research for the Years 2015, 2025 & 2030
  • CHINA
    • HLA Typing for Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 53: China Recent Past, Current & Future Analysis for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for HLA Typing for Transplant by Products & Services - Percentage Breakdown of Value Sales for Reagents & Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for HLA Typing for Transplant by Technology - Percentage Breakdown of Value Sales for Non-Molecular Assay and Molecular Assay for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for HLA Typing for Transplant by Application - Diagnostics and Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for HLA Typing for Transplant by Application - Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for HLA Typing for Transplant by Application - Percentage Breakdown of Value Sales for Diagnostics and Research for the Years 2015, 2025 & 2030
  • EUROPE
    • HLA Typing for Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 62: Europe Recent Past, Current & Future Analysis for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for HLA Typing for Transplant by Products & Services - Percentage Breakdown of Value Sales for Reagents & Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for HLA Typing for Transplant by Technology - Percentage Breakdown of Value Sales for Non-Molecular Assay and Molecular Assay for the Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for HLA Typing for Transplant by Application - Diagnostics and Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for HLA Typing for Transplant by Application - Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for HLA Typing for Transplant by Application - Percentage Breakdown of Value Sales for Diagnostics and Research for the Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for HLA Typing for Transplant by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for HLA Typing for Transplant by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for HLA Typing for Transplant by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
  • FRANCE
    • HLA Typing for Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France Historic Review for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: France 15-Year Perspective for HLA Typing for Transplant by Products & Services - Percentage Breakdown of Value Sales for Reagents & Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 77: France Recent Past, Current & Future Analysis for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for HLA Typing for Transplant by Technology - Percentage Breakdown of Value Sales for Non-Molecular Assay and Molecular Assay for the Years 2015, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for HLA Typing for Transplant by Application - Diagnostics and Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for HLA Typing for Transplant by Application - Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for HLA Typing for Transplant by Application - Percentage Breakdown of Value Sales for Diagnostics and Research for the Years 2015, 2025 & 2030
  • GERMANY
    • HLA Typing for Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 83: Germany Recent Past, Current & Future Analysis for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Germany Historic Review for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Germany 15-Year Perspective for HLA Typing for Transplant by Products & Services - Percentage Breakdown of Value Sales for Reagents & Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Germany 15-Year Perspective for HLA Typing for Transplant by Technology - Percentage Breakdown of Value Sales for Non-Molecular Assay and Molecular Assay for the Years 2015, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for HLA Typing for Transplant by Application - Diagnostics and Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for HLA Typing for Transplant by Application - Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for HLA Typing for Transplant by Application - Percentage Breakdown of Value Sales for Diagnostics and Research for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 92: Italy Recent Past, Current & Future Analysis for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Italy Historic Review for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Italy 15-Year Perspective for HLA Typing for Transplant by Products & Services - Percentage Breakdown of Value Sales for Reagents & Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 95: Italy Recent Past, Current & Future Analysis for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Italy 15-Year Perspective for HLA Typing for Transplant by Technology - Percentage Breakdown of Value Sales for Non-Molecular Assay and Molecular Assay for the Years 2015, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for HLA Typing for Transplant by Application - Diagnostics and Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for HLA Typing for Transplant by Application - Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for HLA Typing for Transplant by Application - Percentage Breakdown of Value Sales for Diagnostics and Research for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • HLA Typing for Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 101: UK Recent Past, Current & Future Analysis for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UK Historic Review for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: UK 15-Year Perspective for HLA Typing for Transplant by Products & Services - Percentage Breakdown of Value Sales for Reagents & Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 104: UK Recent Past, Current & Future Analysis for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: UK 15-Year Perspective for HLA Typing for Transplant by Technology - Percentage Breakdown of Value Sales for Non-Molecular Assay and Molecular Assay for the Years 2015, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for HLA Typing for Transplant by Application - Diagnostics and Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for HLA Typing for Transplant by Application - Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for HLA Typing for Transplant by Application - Percentage Breakdown of Value Sales for Diagnostics and Research for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of Europe Historic Review for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Rest of Europe 15-Year Perspective for HLA Typing for Transplant by Products & Services - Percentage Breakdown of Value Sales for Reagents & Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 113: Rest of Europe Recent Past, Current & Future Analysis for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Rest of Europe Historic Review for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Rest of Europe 15-Year Perspective for HLA Typing for Transplant by Technology - Percentage Breakdown of Value Sales for Non-Molecular Assay and Molecular Assay for the Years 2015, 2025 & 2030
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for HLA Typing for Transplant by Application - Diagnostics and Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Rest of Europe Historic Review for HLA Typing for Transplant by Application - Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Rest of Europe 15-Year Perspective for HLA Typing for Transplant by Application - Percentage Breakdown of Value Sales for Diagnostics and Research for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • HLA Typing for Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 119: Asia-Pacific Recent Past, Current & Future Analysis for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Asia-Pacific Historic Review for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Asia-Pacific 15-Year Perspective for HLA Typing for Transplant by Products & Services - Percentage Breakdown of Value Sales for Reagents & Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Asia-Pacific Historic Review for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Asia-Pacific 15-Year Perspective for HLA Typing for Transplant by Technology - Percentage Breakdown of Value Sales for Non-Molecular Assay and Molecular Assay for the Years 2015, 2025 & 2030
    • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for HLA Typing for Transplant by Application - Diagnostics and Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Asia-Pacific Historic Review for HLA Typing for Transplant by Application - Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Asia-Pacific 15-Year Perspective for HLA Typing for Transplant by Application - Percentage Breakdown of Value Sales for Diagnostics and Research for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 128: Rest of World Recent Past, Current & Future Analysis for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of World Historic Review for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of World 15-Year Perspective for HLA Typing for Transplant by Products & Services - Percentage Breakdown of Value Sales for Reagents & Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of World Recent Past, Current & Future Analysis for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of World Historic Review for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of World 15-Year Perspective for HLA Typing for Transplant by Technology - Percentage Breakdown of Value Sales for Non-Molecular Assay and Molecular Assay for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for HLA Typing for Transplant by Application - Diagnostics and Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of World Historic Review for HLA Typing for Transplant by Application - Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of World 15-Year Perspective for HLA Typing for Transplant by Application - Percentage Breakdown of Value Sales for Diagnostics and Research for the Years 2015, 2025 & 2030

IV. COMPETITION